Onxeo S.A (CPH:ONXEO) (Paris:ONXEO), a clinical-stage biotechnology company, announced on Monday the receipt of a communication from the European Patent Office (EPO) informing the company of its intent to grant a new patent strengthening the European protection of compounds sourced from Onxeo's platON platform.

The company said this new patent strengthens the patent portfolio around AsiDNA, Onxeo's first-in-class DNA Damage Response (DDR) inhibitor. It protects AsiDNA and related compounds, as such and for their therapeutic use, in particular for the treatment of cancers, alone or in combination with other agents such as radiotherapy, chemotherapy or other tumour DNA-damaging agents.

This patent will provide a term of protection valid until mid-2031, which could be further extended until 2036 via the supplementary protection certificate (SPC) system. It completes the already robust set of 9 patent families securing the protection of AsiDNA and its related compounds, Onxeo added.

Onxeo specialises in the development of drugs targeting tumour DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers.